What Mission Bio does

Mission Bio, Inc. is a privately held Delaware-incorporated life-sciences-tools company headquartered in South San Francisco, California, founded in 2012 with 101–250 employees. The company develops and commercializes the Tapestri Platform, which is described as the first and only single-cell technology to simultaneously measure DNA (SNV and CNV), RNA, surface protein, and CpG methylation from the same individual cells. The platform uses targeted amplicon-based panels and droplet-based single-cell isolation, and is sold alongside dedicated assay modules (DNA+Protein, DNA+CpG Methylation, SNV+CNV, DNA+RNA, Single-Cell Genome Integrity, and Single-Cell VCN Assay for CAR-T), as well as supporting software (Tapestri Insights, Tapestri Pipeline, Tapestri Designer) accessed via an AWS-hosted client portal.

Mission Bio serves two primary customer segments: biopharmaceutical companies (drug developers and clinical sponsors using Tapestri for biomarker discovery, trial stratification, and mechanism-of-action studies in oncology, hematologic malignancies, and cell and gene therapy) and academic medical centers and research universities (independent investigators conducting hematology, oncology, and cell-therapy research, with a particularly strong footprint in AML/MRD, multiple myeloma, myeloproliferative neoplasms, and CRISPR-editing characterization). Notable enterprise and academic relationships include Incyte (INCA033989 MPN program, ASH 2025), Heidelberg University Hospital and the BLAST trial consortium, the University of Miami (multiple myeloma), the Human Cell Atlas consortium, and Integrated DNA Technologies (paired rhAmpSeq/Tapestri CRISPR workflow). Key collaborators and clinical co-development sites also include City of Hope, Children's Hospital Colorado, University of Colorado Anschutz, Weill Cornell Medicine, and the New York Genome Center.

The business model combines instrument sales, recurring consumables (reagents, cartridges, kits, panels), enterprise software access, and professional services (Pharma Assay Development for Cell & Gene Therapy and Drug Development). Pricing is quote-based under multi-year enterprise contracts; products are research-use-only and the company holds ISO Certification and operates AWS-hosted infrastructure with HIPAA/GDPR-aligned data practices. The company has raised approximately $150M+ in disclosed equity across Series B (2017–2018), Series C ($70M, 2020, led by Novo Holdings), a 2022 $40M round, and an August 2025 Ally Bridge Group-led round with participation from Agilent, Cota Capital, Mayfield Fund, and Novo Holdings. Recent strategic emphasis is on biopharma clinical adoption, cell-and-gene-therapy QC, and global academic footprint, supported by a leadership team that added a new CMO (Zivjena Vucetic, October 2025) and a new CCO (Matthew Cato, August 2025).

Name

Mission Bio

Legal name

Mission Bio, Inc.

Website

https://missionbio.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

101–250 employees

Short description

Mission Bio develops the Tapestri single-cell multi-omics platform, the only technology co-measuring DNA, RNA, protein, and CpG methylation from the same cells, serving biopharmaceutical companies and academic medical centers in oncology, hematologic malignancies, cell and gene therapy, and CRISPR-editing research.

Ownership category

akta.pro rank

Product category

Single-Cell Multi-omics Instruments and Consumables

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Testing Laboratories and Services (541380)

SIC

Services-Testing Laboratories (8734), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)

akta.pro secondary industry

CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq) (HLAAAIAG)

Keywords

• Single-cell multiomics
• Single-cell DNA sequencing
• Cancer biomarker discovery
• Cell therapy characterization
• Clonal evolution analysis

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Instrument sales (Tapestri hardware): Sells Tapestri instruments and onboard instrument software under Terms and Conditions of Sale; warranty covers devices for one year from pickup date.
2. Reagents, consumables, kits, cartridges, panels: Sells reagents, cartridges, and panels (consumables) on FOB basis with warranty through expiration date. Recurring revenue tied to instrument installed base and ongoing research usage.
3. Pharma Assay Development (PAD) services: Custom assay design and bioinformatics services for biopharma and cell/gene therapy developers (PAD for Cell & Gene Therapy and PAD for Drug Development).
4. Software / bioinformatics access (Tapestri Insights, Pipeline, Designer, Portal): Provides Tapestri Insights, Tapestri Pipeline, Tapestri Designer, and a web-based portal for client data processing and analysis hosted on AWS.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

Mission Bio develops and sells the Tapestri Platform, the first single-cell technology to simultaneously measure DNA (SNV and CNV), RNA, surface protein, and CpG methylation from the same individual cells. The platform combines a proprietary instrument, targeted Panels (DNA + Protein, DNA + CpG Methylation, DNA + RNA, SNV, SNV + CNV), the Tapestri Insights/Pipeline/Designer bioinformatics software suite, and custom Pharma Assay Development (PAD) services for cell and gene therapy and oncology drug development customers. Mission Bio also offers the Single-Cell Genome Integrity Solution and the Single-Cell VCN Assay for advanced therapy safety characterization.

Product overview

Mission Bio operates a single unified platform-plus-modules architecture centered on the Tapestri Platform, the first single-cell technology to simultaneously measure DNA (SNV/CNV), RNA, protein, and CpG methylation from the same cells. The core platform is augmented by (a) targeted Panels (SNV, SNV+CNV, DNA+Protein, DNA+CpG Methylation, DNA+RNA), (b) software components Tapestri Insights, Tapestri Pipeline, and Tapestri Designer for analysis, design, and visualization, (c) the Pharma Assay Development (PAD) service with sub-offerings PAD for Cell & Gene Therapy and PAD for Drug Development, and (d) dedicated assay modules such as the Single-Cell Genome Integrity Solution and the Single-Cell VCN Assay. Together these pieces form an end-to-end workflow from sample preparation through publication-ready multi-omic insights used globally for oncology research, hematologic malignancies, cell and gene therapy development, and precision medicine biomarker discovery.

Differentiator

Problem solved

Functional benefit

Brands

• Tapestri Platform: Mission Bio's flagship single-cell multi-omics platform offering end-to-end workflow from sample preparation to visualization with DNA, RNA, protein, and CpG methylation readouts.

Products and services

• Tapestri Platform End-to-end single-cell multiomics workflow from sample preparation to visualization with publication-ready insights. The first and only single-cell technology developed to reveal biomarkers that stratify patients, signal resistance, and predict relapse by connecting genotype and phenotype at single-cell resolution. Sells Tapestri instruments, onboard instrument software, reagents, cartridges, panels, and bioinformatics software (Tapestri Insights, Tapestri Pipeline, Tapestri Designer).
• Panels Targeted consumable panels (DNA + Protein, DNA + CpG Methylation, DNA + RNA, SNV, SNV + CNV) that focus on key regions of interest for efficient use of sequencing budget and analysis time on the Tapestri Platform. Sold on FOB basis with warranty through expiration date; recurring revenue tied to instrument installed base.
• Pharma Assay Development (PAD) Custom assay development service for pharmaceutical and biopharma customers, including custom panel design, assay optimization, and complex single-cell data analysis with bioinformatics support to support clinical development and biomarker discovery.
• PAD for Cell & Gene Therapy Specialized pharma assay development service for cell and gene therapy programs, including custom VCN amplicon panel design, on/off-target editing analysis, and genome integrity assessment for advanced therapy developers.
• PAD for Drug Development Pharma assay development service tailored for drug development workflows, supporting biomarker discovery, mechanism-of-action studies, and patient stratification in oncology and hematology programs.
• Tapestri Single-Cell Genome Integrity Solution Single-cell solution that measures whole-genome copy number variation at single-cell resolution in advanced therapies and tumor samples, addressing safety assessment for cell and gene therapy manufacturing.
• scG2P Single-Cell Profiling Technique Single-cell profiling technique co-developed with Weill Cornell Medicine and the New York Genome Center that maps pre-malignant gene mutations in solid tissues; published in Cancer Discovery.
• Tapestri Single-Cell Sequencing Service Service-based access to the Tapestri Platform offered to research customers (e.g., through Avancebio and academic core facilities) for outsourced single-cell multi-omics experiments.

Quantifiable outcome

• Single-cell transduction assay achieved 99.2% to 99.9% sensitivity and 98.8% to 99.6% specificity in CAR-T vector copy number measurement
• +4 more outcomes

Named customers13 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability6 records

Feature9 records

Partnerships

14 partnerships are on record, tiered flagship, core and minor.

• Human Cell Atlas (HCA)flagshipStrategic or Co-development Partner · 9 June 2026Collaboration giving HCA members discounted access to Mission Bio's Tapestri Platform for single-cell multiomics analysis. Includes access to validated assays, bioinformatics support, and custom assay development capabilities for research across genomics, transcriptomics, proteomics, and related omics fields. Announced ahead of the HCA General Meeting 2026 (June 16–18, Boston).
• Heidelberg University HospitalcoreStrategic or Co-development Partner · 3 June 2026Scientific coordination of the randomized phase II BLAST clinical trial in AML; retrospective Tapestri analysis identified CXCR4 as a predictive biomarker for Motixafortide in AML (results published in Blood, 2026).
• Martin Luther University Halle-WittenbergcoreStrategic or Co-development Partner · 3 June 2026Sponsor of the investigator-initiated BLAST phase II clinical trial in AML (128 patients across 29 academic centers in Germany); Tapestri was used for retrospective single-cell analysis of bone marrow samples.
• East German Study Group for Hematology and Oncology (OSHO)minorOthers · 3 June 2026Active supporter of the BLAST phase II AML trial; Mission Bio conducted retrospective single-cell analysis on trial samples using Tapestri.
• Study Alliance Leukemia (SAL)minorOthers · 3 June 2026Active supporter of the BLAST phase II AML trial with Mission Bio Tapestri retrospective analysis.
• City of HopecoreStrategic or Co-development Partner · 30 April 2026Collaboration on the Molecular Therapy Advances publication using Tapestri to profile vector copy number (VCN), surface protein expression, and vector integrity across ~10,000 individual CAR-T cells in a single assay.
• Children's Hospital ColoradocoreStrategic or Co-development Partner · 30 April 2026Collaborator on the Tapestri CAR-T vector copy number study published in Molecular Therapy Advances, demonstrating 99.2%–99.9% sensitivity and 98.8%–99.6% specificity.
• University of Colorado AnschutzcoreStrategic or Co-development Partner · 30 April 2026Collaborator on the Tapestri CAR-T vector copy number study published in Molecular Therapy Advances.
• Weill Cornell MedicinecoreStrategic or Co-development Partner · 15 January 2026Co-developed the scG2P single-cell profiling technique that maps pre-malignant gene mutations in solid tissues, published in Cancer Discovery. Found that more than half of over 10,000 sampled esophageal cells contained clonal driver mutations, with NOTCH1 most common.
• New York Genome CentercoreStrategic or Co-development Partner · 15 January 2026Collaboration with Mission Bio and Weill Cornell Medicine to develop the scG2P single-cell profiling technique for pre-malignant mutations in solid tissues.
• IncyteflagshipStrategic or Co-development Partner · 4 December 2025Tapestri Platform supported exploratory biomarker analysis for Incyte's INCA033989 clinical trial for myeloproliferative neoplasms (MPNs), with data presented at ASH 2025. Single-cell DNA and protein profiling enabled Incyte to better characterize clonal diversity, track resistance mechanisms, and refine patient stratification strategies.
• Bar-Ilan University (Hendel lab)coreStrategic or Co-development Partner · 21 May 2025Research collaboration using paired rhAmpSeq + Tapestri workflow for multi-scale characterization of CRISPR editing outcomes in primary human T cells (targeting PDCD1, TCRA, TCRB); published as a Mission Bio technical note.
• Integrated DNA Technologies (IDT)coreStrategic or Co-development Partner · 6 May 2025Partnership to advance single-cell precision in CRISPR genome editing analysis. Pairs IDT's rhAmpSeq bulk population-level assay with Mission Bio's Tapestri single-cell multiomics for two-tier CRISPR editing characterization (99.77%–99.93% indel detection, novel translocations in as few as 1 in 25,000 cells).
• University of MiamicoreStrategic or Co-development Partner · 2 December 2024Partnership with top researchers from the University of Miami to accelerate early relapse detection and treatment selection of multiple myeloma patients using the Tapestri Platform.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Emerging players

• Akoya Biosciences: Akoya's CODEX and Phenoptics spatial biology platforms compete for the same immuno-oncology and translational research budgets as Tapestri. While Akoya focuses on spatial proteomics rather than genotype-phenotype co-measurement, both are positioning around single-cell-level biomarker discovery.
• Cytek Biosciences: Cytek's spectral flow cytometry platforms (Aurora, Northern Lights) compete for immunology and immuno-oncology research dollars alongside Mission Bio's DNA+Protein assay. Both enable high-dimensional single-cell phenotyping in translational and clinical research settings.
• Parse Biosciences: Parse offers scalable single-cell RNA sequencing (Evercode) without instrument requirements, targeting the same translational and academic customer base as Mission Bio. It represents an emerging competitive alternative for hypothesis-generation use cases that today are adjacent to Tapestri's targeted panels.
• Singular Genomics: Singular's G4 sequencing platform serves the same translational and clinical research sequencing market that underpins Tapestri's workflow. While not a direct single-cell competitor, Singular represents an alternative sequencing backbone for customers building single-cell pipelines.

Direct peers

• Standard BioTools (formerly Fluidigm): Standard BioTools historically pioneered single-cell targeted DNA/multi-omics workflows (Hyperion, CyTOF, Advanta) and directly competes with Tapestri in targeted single-cell genomics and immuno-oncology profiling. Both serve translational research and biopharma customers with single-cell assays.

Regional players

• Element Biosciences: Element's AVITI sequencing platform enables lower-cost sequencing that complements or substitutes for upstream single-cell library prep platforms. As a next-gen sequencing platform vendor, Element is an ecosystem peer for customers evaluating end-to-end single-cell multi-omics workflows.

Broad incumbents

• BD Biosciences (BD Rhapsody): BD's Rhapsody single-cell analysis platform competes with Tapestri in targeted and whole-transcriptome single-cell sequencing, particularly in immunology and oncology research. BD offers broader flow cytometry and reagent portfolios versus Mission Bio's focused multi-omics platform.
• Bio-Rad Laboratories: Bio-Rad's ddPCR and Droplet Digital PCR products are the gold-standard bulk alternative to Tapestri for cell therapy QC (e.g., vector copy number). Bio-Rad represents both a competitive incumbent in CAR-T characterization and a logical strategic acquirer of Mission Bio's single-cell multi-omics platform.
• NanoString Technologies (Bruker Spatial Biology): NanoString's nCounter and GeoMx platforms compete for oncology translational research spend alongside Tapestri. Both serve biopharma biomarker discovery workflows, though NanoString emphasizes spatial and bulk molecular profiling rather than single-cell multi-omics.
• 10x Genomics: 10x Genomics is the dominant single-cell sequencing platform (Chromium) with a much larger installed base and whole-transcriptome focus. It is the primary competitive threat to Mission Bio's Tapestri, increasingly extending into targeted multi-omics and cell-therapy characterization applications.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/missionbio
• Facebookfacebook.com/missionbio
• LinkedInlinkedin.com/company/mission-bio

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds11 records

Investors28 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mission Bio